BioVersys

News

Shionogi puts up to $600m behind BioVersys antibiotics

Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.

News

Dr Marc Gitzinger, chief executive of BioVersys

AMR biotech BioVersys plans to float on Swiss stock exchange

BioVersys has filed to list on the Swiss Stock Exchange, hoping to raise CHF80m for its novel antibacterial candidates.

News

A close-up of a Mycobacterium tuberculosis culture

GSK commits to further support of BioVersys’ TB drug

GSK has expanded a collaboration with BioVersys on a new drug candidate for tuberculosis (TB) and contributed to an extension to the Swiss biotech’s third-round financing.

Shionogi puts up to $600m behind BioVersys antibiotics

AMR biotech BioVersys plans to float on Swiss stock exchange

GSK commits to further support of BioVersys’ TB drug

Tenax trounced by phase 3 heart failure readout

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks